MUMBAI, India, Aug. 31 -- Intellectual Property India has published a patent application (202617081742 A) filed by Flindr Therapeutics B. V. on July 02, 2026, for Compounds.
Inventors include Ligtenberg, Maarten Alexander; Wijkmans, Jacobus Cornelis Henricus Maria; Urbanska, Ewelina Anna; Shouksmith, Andrew Eric; Samarskaya, Alina; and Travagli, Massimiliano Application Number.
The application for the patent was published on August 28, 2026, under issue no. 35/2026.
Abstract: The present invention relates to [3-(sulphonyl or sulfonimidoyl)prop-2-en-1-yl]carboxamide derivatives having the formula (I) or the pharmaceutical acceptable salt or prodrug thereof. The present invention further relates to the compound according to the invention for use in therapy, particularly for the treatment of cancer. The present invention further relates to a method for inhibiting Met1-linked ubiquitination. The present invention also relates to a pharmaceutical composition comprising the compound of the present invention.
Disclaimer: Curated by HT Syndication.
